FindTrial
Sign In

Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism

Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism - Study on serum butyrylcholinesterase activity of rivastigmine transdermal preparation in patients with Alzheimer type dementia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027492
Enrollment
140
Registered
2017-05-25
Start date
2017-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Altzheimer&#39

Interventions

Rivastigmine group: Rivastatch patch 9 mg, Rivasutatch patch 18 mg Among the dosage and dose stated in the package insert, administration starts from 9 mg once a day, in principle, it increases to 18

Sponsors

Medical Corporation Kudoh Chiaki Neurosurgery Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with mild and moderate Alzheimer's type dementia with complications of either hyperlipidemia, hypertension, or diabetes.

Exclusion criteria

Exclusion criteria: Patients with history of hypersensitivity to rivastigmine, components of donepezil hydrochloride or carbamate derivatives

Design outcomes

Primary

MeasureTime frame
Change in serum BuChE activity, change in cognitive function severity evaluation (MMSE, ADAS-J) at registration, 3 months after administration, 6 months after administration—

Secondary

MeasureTime frame
TG, LDL, HDL, HbA1c, GOT, GPT, pancreatic amylase, MRI (VSRAD), blood pressure, pulsatility at the time of registration, 3 months after administration, 6 months after administration—

Countries

Japan

Contacts

Public ContactKudoh Chiaki

Medical Corporation Kudoh Chiaki Neurosurgery Clinic Neurosurgery

kudouchiaki@yahoo.co.jp03-5767-0226

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026